Garcilaso Riesco-Eizaguirre
Overview
Explore the profile of Garcilaso Riesco-Eizaguirre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Lloveras H, Zafon C, Iglesias C, Marcos-Ruiz J, Gil J, Rueda-Pujol A, et al.
Thyroid
. 2025 Mar;
PMID: 40045915
Distant metastases (DM) are the leading cause of thyroid cancer-related death in patients with differentiated thyroid cancer (DTC). Despite significant progress in understanding DNA methylation in DTC, the methylation landscape...
2.
Perez-Fernandez L, Sastre J, Zafon C, Oleaga A, Castelblanco E, Capel I, et al.
Front Endocrinol (Lausanne)
. 2023 Jan;
13:1071775.
PMID: 36714606
Introduction: The dynamic risk stratification (DRS) is a relatively new system in thyroid cancer that considers the response to primary treatment to improve the initial risk of recurrence. We wanted...
3.
Zaballos M, Acuna-Ruiz A, Morante M, Riesco-Eizaguirre G, Crespo P, Santisteban P
Cell Mol Life Sci
. 2022 Sep;
79(9):504.
PMID: 36056964
Background: RAS-to-ERK signaling is crucial for the onset and progression of advanced thyroid carcinoma, and blocking ERK dimerization provides a therapeutic benefit in several human carcinomas. Here we analyzed the...
4.
Montero-Conde C, Leandro-Garcia L, Martinez-Montes A, Martinez P, Moya F, Leton R, et al.
Clin Transl Med
. 2022 Aug;
12(8):e1001.
PMID: 35979662
Background: Comprehensive molecular studies on tumours are needed to delineate immortalization process steps and identify sensitive prognostic biomarkers in thyroid cancer. Methods And Results: In this study, we extensively characterize...
5.
Ramirez-Moya J, Wert-Lamas L, Acuna-Ruiz A, Fletcher A, Wert-Carvajal C, McCabe C, et al.
Sci Rep
. 2022 May;
12(1):7706.
PMID: 35562181
Thyroid cancer is the most common primary endocrine malignancy in adults and its incidence is rapidly increasing. Long non-coding RNAs (lncRNAs), generally defined as RNA molecules longer than 200 nucleotides...
6.
Miljus J, Guillen-Sacoto M, Makiadi-Alvarado J, Wert-Lamas L, Ramirez-Moya J, Robledo M, et al.
J Clin Endocrinol Metab
. 2022 Jan;
107(5):1280-1293.
PMID: 35022762
Context: Circulating microRNAs (miRNAs) are emerging biomarkers of thyroid cancer. Objective: This study sought to identify the profile of circulating miRNAs and its response to human recombinant TSH (rhTSH) in...
7.
Riesco-Eizaguirre G, Santisteban P, De la Vieja A
Endocr Relat Cancer
. 2021 Aug;
28(10):T141-T165.
PMID: 34387194
The sodium/iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates active iodide transport into the thyroid gland and into several extrathyroidal tissues. NIS-mediated iodide uptake plays a pivotal...
8.
Tao Y, Wang F, Shen X, Zhu G, Liu R, Viola D, et al.
J Clin Endocrinol Metab
. 2021 Jul;
106(11):3228-3238.
PMID: 34273152
Context: How lymph node metastasis (LNM)-associated mortality risk is affected by BRAF V600E in papillary thyroid cancer (PTC) remains undefined. Objective: To study whether BRAF V600E affected LNM-associated mortality in...
9.
De la Vieja A, Riesco-Eizaguirre G
Cancers (Basel)
. 2021 Mar;
13(5).
PMID: 33673669
Thyroid radio-iodide therapy (RAI) is one of the oldest known and used targeted therapies. In thyroid cancer, it has been used for more than eight decades and is still being...
10.
Paja M, Zafon C, Iglesias C, Ugalde A, Cameselle-Teijeiro J, Rodriguez-Carnero G, et al.
Endocrine
. 2021 Jan;
73(1):131-140.
PMID: 33484411
Purpose: To determine the rate of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in a multi-institutional series from the Iberian Peninsula and describing this NIFTP cohort. Methods: Retrospective...